Related Experiment Video
Updated: Jul 25, 2025
Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles
Published on: November 17, 2018
Neoantigens in cancer immunotherapy: quantity vs. quality
Yochai Wolf1,2, Yardena Sameuls3
1Ella Lemelbaum Institute for Immuno-oncology, Sheba Medical Center, Ramat Gan, Israel.
Abstract:
Traditional immunotherapies provide clinical benefits to only a few patients with solid tumors, highlighting the urgent need for more effective approaches. Traditional immunotherapies rely on the presentation of cancer antigens, with neoantigens being highly important in this context as they are specific to malignant tissue but not healthy tissue. The quantity of neoantigens is often associated with clinical benefit, but it cannot fully explain or predict patient response. In this Viewpoint, we highlight several qualitative aspects that should be considered in neoantigen-based therapy. We emphasize the distinction between private and recurrent neoantigens, discuss the importance of neoantigen clonality, and describe new subtypes of neopeptides that further diversify the potential of neoantigens in immunotherapy.
Insights
Neoantigen-based cancer immunotherapies show promise but require deeper understanding beyond quantity. Qualitative factors like neoantigen type and clonality are crucial for predicting patient response and improving treatment effectiveness.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Traditional immunotherapies offer limited clinical benefits for solid tumors.
- Current immunotherapies depend on cancer antigen presentation, with neoantigens being key.
- Neoantigen quantity correlates with, but doesn't fully predict, treatment success.
Purpose of the Study:
- To explore qualitative aspects of neoantigens beyond mere quantity.
- To enhance the understanding of neoantigen-based immunotherapy strategies.
- To identify factors influencing patient response to neoantigen-targeted therapies.
Main Methods:
- Review and synthesis of current research on neoantigens in cancer immunotherapy.
- Analysis of qualitative neoantigen characteristics, including private vs. recurrent neoantigens.
- Discussion of neoantigen clonality and novel neopeptide subtypes.
Main Results:
- Neoantigen quantity alone is insufficient for predicting immunotherapy outcomes.
- Distinguishing between private and recurrent neoantigens offers deeper insights.
- Neoantigen clonality and new neopeptide subtypes represent critical qualitative factors.
Conclusions:
- Qualitative assessment of neoantigens is essential for advancing cancer immunotherapy.
- Considering neoantigen characteristics beyond quantity can improve treatment efficacy.
- Further research into neoantigen subtypes and clonality will diversify immunotherapy potential.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:26Antigens Involved in Adaptive Immunity
Complete Antigens
Complete antigens possess both immunogenicity and...